This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. Timothy Greenamyre, MD, PHD
Departments of Neurology, Neurobiology and Anatomy, and Pharmacology University of Rochester 601 Elmwood Ave, Box 673 Rochester, NY 14642

Arch Neurol. 1992;49(9):901.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—I appreciate the comments by Weller and Kornhuber on our article.¹ Although we confined our review to the potential use of N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease only, we certainly agree with the notion that these agents may be beneficial in other conditions. While it is well known that sudden withdrawal of dopaminergic antiparkinsonian medications may precipitate neuroleptic malignant syndrome (NMS),² it is less widely appreciated that abrupt cessation of amantadine (a commonly used antiparkinsonian medication and a noncompetitive NMDA antagonist) may be associated with a profound exacerbation of parkinsonism³ and a condition marked by severe rigidity (J.T.G., unpublished observations, 1992), even with continued therapy with levodopa or a dopamine agonist. Could this represent a forme fruste or variant of NMS? Perhaps the full NMS is not seen in these cases because of the fact that there is ongoing dopaminergic therapy. It . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?